Related Experiment Video
Updated: May 11, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Does L-carnitine improve endothelial function in hemodialysis patients?
Mohammad Reza Sabri1, Farnaz Fahimi, Soheila Hajialiasgar
1Child Growth and Development Research Center, Department of Pediatric Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Insights
Oral L-carnitine did not improve endothelial function in hemodialysis patients after one month. Further research with larger sample sizes and different administration methods is needed to clarify L-carnitine
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Nutritional Science
Background:
- Atherosclerosis is a primary cause of mortality in hemodialysis patients.
- Hemodialysis patients frequently experience L-carnitine deficiency due to renal impairment.
- Endothelial dysfunction is a significant concern in this patient population.
Purpose of the Study:
- To evaluate the efficacy of oral L-carnitine supplementation in improving endothelial function in chronic hemodialysis patients.
- To assess the impact of L-carnitine on flow-mediated dilation and carotid intima-media thickness.
Main Methods:
- A randomized clinical trial involving 31 adult chronic hemodialysis patients.
- Participants were assigned to receive either oral L-carnitine (1500 mg/dialysis interval) or a placebo for one month.
- Endothelial function was assessed using ultrasonographic measurements of flow-mediated dilation and carotid intima-media thickness.
Main Results:
- One month of oral L-carnitine therapy showed no statistically significant improvement in flow-mediated dilation (p = 0.80).
- No significant decrease in carotid intima-media thickness was observed with L-carnitine treatment (p = 0.12).
- Placebo group also showed no significant changes in the measured endothelial function parameters.
Conclusions:
- Oral L-carnitine administration for one month did not enhance endothelial function in hemodialysis patients.
- The current findings suggest a limited role for short-term oral L-carnitine in this context.
- Further investigation with larger cohorts, longer durations, and potentially intravenous L-carnitine is warranted.
Background:
Atherosclerosis is the leading cause of death in hemodialysis patients. These patients are also very prone to L-carnitine deficiency due to kidney disease. In this clinical trial, we investigated the effect of oral L-carnitine on endothelial function of these patients.
Materials And Methods:
[corrected] We studied 31 adult chronic hemodialysis patients in our center and divided them into two groups. The first group (n = 20) received 1500 mg/dialysis interval (every other day) oral L-carnitine. The control group (n = 11) received placebo for one month. Ultrasonographic measurements of flow mediated dilation and carotid intima-media thickness were performed before and after one month of L-carnitine and placebo therapy.
Results:
This study showed that after one month of L-carnitine or placebo therapy there was no significant improvement in flow mediated dilation (p = 0.80 and p = 0.59, respectively) or decrease in carotid intima-media thickness (p = 0.12 and p = 0.50, respectively).
Conclusions:
Our study revealed that one month of oral L-carnitine therapy did not improve endothelial function in hemodialysis patients. Long-term studies with large sample size using intravenous form and higher doses of the drug are required to clarify the questionable role of L-carnitine in hemodialysis patients.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Chronic Kidney Disease III: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Hemodialysis II: Procedure and Complications
